• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 12, 2014

View Archived Issues

Investor 'hurRAA' for Mannkind: Sanofi pays potential $925M for Afrezza inhaled insulin

No longer left to its own devices in putting Afrezza inhaled insulin on the market, Exubera-haunted Mannkind Corp. landed an eagerly awaited commercialization deal with Sanofi SA that brings $150 million up front and as much as $775 million in regulatory, development and sales milestone payments for the second-generation product. Read More

FDA gets second biosimilar application in less than a month

The biosimilar pipeline is starting to flow in the U.S. with the FDA receiving its second 351(k) biologic license application (BLA) in less than a month. Celltrion Inc. reported Monday that it has filed a BLA for its Remsima, a biosimilar of Janssen Biotech Inc.'s Remicade (infliximab). Read More

Forward Pharma files for IPO as it prepares to battle Biogen

Forward Pharma A/S, a Danish biotech developing a dimethyl fumarate (DMF) therapy for immune disorders, filed to raise up to $200 million in an initial public offering (IPO) that revealed at least one of the company's patents could conflict with a central claim protecting Biogen Idec Inc.'s Tecfidera, a fast-rising DMF-based multiple sclerosis (MS) therapy. Read More

Cost-benefit criteria for Roche's Kadcyla don't fly with NICE

LONDON – The UK's National Institute for Health and Care Excellence (NICE) has refused to approve payment for Roche AG's breakthrough breast cancer drug Kadcyla (trastuzumab emtansine), undermining a new voluntary pricing scheme that is intended to ensure better access to innovative drugs. Read More

Pharmathene wins another victory in smallpox saga

Pharmathene Inc. won another moral victory when the Delaware Court of Chancery issued a ruling in its long-running dispute with Siga Technologies Inc. over the smallpox antiviral, tecovirimat. The court awarded Annapolis, Md.-based Pharmathene a lump sum payment – though the amount from a complex payment formula remains to be seen – for damages arising from the value of lost profits from sales of tecovirimat (previously ST-246 and Arestvyr). Read More

Chinese court sentences GSK-linked investigators to prison

HONG KONG ­– Shanghai No. 1 Intermediate People's Court sentenced two foreign private investigators linked to the Glaxosmithkline plc (GSK) China bribery scandal to prison on Monday. Read More

Researchers resolve bone development debate

HONG KONG – Researchers here have shown for the first time that during bone formation and growth, cartilage cells or chondrocytes survive and develop into mature osteoblasts, the cells that form new bone, contradicting the long-held tenet that chondrocytes and osteoblasts are separate independently developing cell types. Read More

EMA speeds up integration of genomic biomarkers into clinical development

LONDON – A rapid advance in the underlying technologies coupled with the increasing ability to correlate genomic biomarkers with health and disease has yet to translate through to tools that are systematically applied to inform clinical development and guide the subsequent use of drugs. Read More

News from Washington

Eisai Inc., of Woodcliff Lake, N.J., filed suit last week against the FDA to force the agency to restore the full five-year new chemical entity exclusivity to its obesity and epilepsy drugs, which are both controlled substances. Read More

Financings

Tapimmune Inc., of Seattle, said it entered a definitive agreement with an unnamed institutional investor for a registered direct placement of $2 million of common stock at $1.06 apiece. Read More

Stock movers

Read More

Earnings

Cardiome Pharma Corp., of Vancouver, British Columbia, recorded a net loss of $4.2 million, or 26 cents per common share, for the three months ending June 30, compared to a net loss of $2.8 million, or 22 cents per common share, for the same period in 2013. Read More

Other news to note

Thrombogenics NV, of Leuven, Belgium, said the Scottish Medicines Consortium (SMC) issued a positive recommendation for the use of Jetrea (ocriplasmin) to treat adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Read More

In the clinic

Concordia Healthcare Corp., of Oakville, Ontario, said its subsidiary Pinnacle Biologics Inc. enrolled the first patients in a randomized phase II trial to evaluate Photodynamic Therapy with Photofrin for patients with epithelioid malignant pleural mesothelioma. Read More

Pharma: Other news to note

Allergan Inc., of Irvine, Calif., received a request for additional information under the Hart-Scott-Rodino Act from the U.S. Federal Trade Commission in connection with Laval, Quebec-based Valeant Pharmaceuticals International Inc.'s unsolicited acquisition proposal. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe